Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 785 posts found.

astrazeneca_sign_sky

First for Japan with the approval of AstraZeneca’s Lokelma in hyperkalaemia

March 26, 2020
Sales and Marketing AstraZeneca, Astra|Zeneca, Japan, Lokelma, hyperkalaemia, pharma

Japan’s Ministry of Health, Labour and Welfare has awarded approval to AstraZeneca’s Lokelma for the treatment of hyerkalaemia, marking the …

News
partnership

AstraZeneca to leverage Silence Therapeutics’ siRNA expertise in $480mn deal

March 25, 2020
Research and Development, Sales and Marketing AstraZeneca, Silence Therapeutics, collaboration, pharma

Silence Therapeutics has revealed it has struck a new collaboration with AstraZeneca which will trigger the “acceleration and re-prioritisation of …

News
astrazeneca_plaque

Japan grants orphan drug designation to Lynparza for BRCA+ unresectable pancreatic cancer

March 19, 2020
Research and Development, Sales and Marketing AstraZeneca, Japan, lynparza, pharma

AstraZeneca has confirmed that its PARP inhibitor Lynparza (olaparib) has been awarded orphan drug designation in Japan for the maintenance …

News
astrazeneca_building_white

Success and failure at Phase 3 for AstraZeneca’s Imfinzi combos in first-line small cell lung cancer

March 17, 2020
Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, pharma

AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …

News
shutterstock_38078521

AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer

March 13, 2020
Medical Communications, Research and Development AstraZeneca, cediranib, lynparza, pharma, trial failure

Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined …

News
az_logo

Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer

March 6, 2020
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure

New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …

News
1740294_bertil-lindmark-webbnyhet

Galecto hires new Chief Medical Officer

February 7, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Galecto

Galecto has announced Bertil Lindmark as their new Chief Medical Officer. He began his posting on 1 February 2020.Lindmark joins …

Appointment

Insider Interview: Reducing the risk of adverse cardiovascular events

February 3, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Insider Interview, cardiovascular, heart disease, pharma

Rodrigo Gribble, Vice President Cardiovascular at AstraZeneca, breaks down recently published data from the PEGASUS trial of ticagrelor, a potential …

Feature

No NICE recommendation for AstraZeneca’s Tagrisso in EGFR+ lung cancer

January 22, 2020
Research and Development, Sales and Marketing AstraZeneca, NICE, Tagrisso, pharma

AstraZeneca’s Tagrisso (osimertinib) has been knocked back for routine use on the NHS in England and Wales by the drug …

News
lynparza

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

January 16, 2020
Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …

News

AstraZeneca to discontinue trial for heart disease drug Epanova

January 13, 2020
Sales and Marketing AstraZeneca, Phase II Trial, Phase III trial, heart disease, triglycerides

AstraZeneca expects a $100 million writedown for its heart disease drug Epanova, as it discontinues its late stage trial. This …

News
5204602349_c87b204860_b

FDA gives a priority review for key heart failure drug Farxiga

January 6, 2020
Sales and Marketing AstraZeneca, Heart Failures, farxiga

The FDA has accepted a New Drug Application (sNDA) and has granted a priority review for AstraZeneca’s drug Farxiga (dapagliflozin) …

News

AstraZeneca’s drug Lokelma approved in China

January 6, 2020
Sales and Marketing AstraZeneca, China, FDA, eu commission, kidney failure, potassium

AstraZeneca’s Lokelma has been approved by the National Medical Products Administration in China. This is due to positive results based …

News
astrazeneca-sign

AstraZeneca’s triple combination therapy for patients with COPD approved in China

December 23, 2019
Sales and Marketing AstraZeneca, COPD, China, respiration

AstraZeneca has announced that budesonide-glycopyrroniunm-formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease …

News
astrazeneca_sign_sky

FDA gives accelerated approval to AstraZeneca and Daiichi’s breast cancer drug

December 23, 2019
Sales and Marketing AstraZeneca, Breast Cancer drug, Cancer, breast cancer, skin cancer

The FDA has approved the breast cancer drug Enhertu, developed by AstraZeneca and Daiichi Sankyo. José Basel, the Executive Vice …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025